InsiderTrades

Form 4 for UNCY Unicycive Therapeutics, Inc.

Accepted 2023-07-13 00:00:00 ET · period of report 2023-07-11 · accession 0001213900-23-056848 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-07-13 2023-07-11 UNCY Gupta Shalabh K. CEO, Dir M - OptEx — +104.6K 2.53M +4% —
DM 2023-07-13 2023-07-11 UNCY Gupta Shalabh K. CEO, Dir M - OptEx $1,000.00 +266.5K 72.0K New +$266.52M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-07-11 M A 104,612 — 2,527,449 D — — (F1) The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share.
2 Derivative Warrant (right to buy) 2023-07-11 M A 115,275 — 115,275 D $0.74 · 2023-07-11 to — 115,275 Series A-5 Convertible Preferred Stock (F1) The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share. (F5) The Tranche C Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's public disclosure of financial results for four (4) quarters of commercial sales of Renazorb following receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb, commencing with the first quarter in which the Company receives revenue from Centers for Medicare and Medicaid Services for Renazorb under the Transitional Drug Add-On Payment Adjustment.
3 Derivative Warrant (right to buy 2023-07-11 M A 79,252 — 79,252 D $0.54 · 2023-07-11 to — 79,252 Series A-3 Convertible Preferred Stock (F1) The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share. (F3) The Tranche A Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Issuer's announcement of receipt of FDA approval for Renazorb.
4 Derivative Series A-1 Convertible Preferred Stock 2023-07-11 M D 50 $1,000.00 0 D $0.49 · — to — — Common Stock (F2) On July 11, 2023, the shares of Series A-1 Convertible Preferred Stock automatically converted into units consisting of (1) 104,612 shares of common stock, (2) a Tranche A Warrant to purchase 79,252 shares of Series A-3 Convertible Preferred Stock, (3) a Tranche B Warrant to purchase 72,047 shares of Series A-4 Convertible Preferred Stock and (4) a Tranche C Warrant to purchase 115,275 shares of Series A-5 Convertible Preferred Stock. The shares of Series A-1 Convertible Preferred Stock had no expiration date prior to conversion.
5 Derivative Warrant (right to buy) 2023-07-11 M A 72,047 — 72,047 D $0.59 · 2023-07-11 to — 72,047 Series A-4 Convertible Preferred Stock (F1) The reported securities were included within the units issued to the reporting person upon conversion of the Series A-1 Convertible Preferred Stock. The Series A-1 Convertible Preferred Stock converted into units at an exercise price of $0.49 per share. (F4) The Tranche B Warrants issued to the reporting person as part of the units issued upon conversion of the Series A-1 Convertible Preferred Stock expire twenty-one (21) days following the Company's announcement of receipt of Transitional Drug Add-On Payment Adjustment approval for Renazorb.